<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND AIM: The LMO2 gene encodes a transcription factor that regulates key events in erythropoiesis, <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, and embryogenesis and is highly expressed at the most immature stages of lymphopoiesis </plain></SENT>
<SENT sid="1" pm="."><plain>Its implication in Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) is limited in the literature </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIAL AND METHODS: An immunohistochemical study was performed on 68 <z:hpo ids='HP_0002665'>lymphoma</z:hpo> specimens showing different types including Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (23), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (10) and diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (35) </plain></SENT>
<SENT sid="3" pm="."><plain>Also, seven specimens of the reactive nodal tissue were included as control </plain></SENT>
<SENT sid="4" pm="."><plain>A monoclonal anti-human antibody has been used to detect LMO2 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: LMO2 was detected in <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> (100%), in nine cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> (90%) and in <z:hpo ids='HP_0000001'>all</z:hpo> cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> of germinal center (GC) subtype 20/35 (57.1%) but is completely negative in non-germinal center (NGC) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:mpath ids='MPATH_458'>normal</z:mpath> control of reactive nodes, LMO2 was expressed in germinal center area but not expressed in other areas including mantle, marginal, or T cell zones </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>; there was no statistically significant relation between LMO2 positive cases and the studied clinicopathological parameters including patient's age, sex and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> site, stage and histological subtype </plain></SENT>
<SENT sid="8" pm="."><plain>On the other hand, it was statistically significant regarding immunophenotyping of GC versus NGC </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: LMO2 expression is a special feature of GC <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> which can be used as a diagnostic marker and therapeutic target </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies regarding its prognostic role in patients are recommended </plain></SENT>
</text></document>